CANCER BIOMARKER DISCOVERY & RX PRECLINICAL RESEARCH
ABOUT US
Somatolink Foundation, inc is a US (Delaware) incorporated "Public Benefit Corporation" research organization "in general partnership with" the ISOPROG-Somatolink EPFP Research Network established by Dr Scalia and Dr Williams in 2017 as an international research program bearing advanced applicable knowledge in the area of cancer biomarker discovery and personalized genomics with multidisciplinary basic and translational collaborations in other health-related fields towards supporting advanced services in personalized drug/cell-gene therapy development and training. The organization founders bears former NIH federal grant and private funding experience and personal network to synergize with the seed capital raising goals.
OUR RESEARCH
Our network’s cancer research provides constant opportunity for diagnostic and therapeutic exploitation
Backed by co-founders previous patenting and ongoing IP consolidation in the area of Targeted-Protein
Degradation and bifunctional molecular solutions for the team’s validated biological targets.
Prospect investors and technical collaborators can register here and download a white paper relative to
our updated R&D pipeline or contact us to inquire about current partnership opportunities